Aridis Pharmaceuticals  © 2009-2014 Le3 Web Designs

Site Map   |   Privacy Policy   |   Financial Conflict of Interest Policy


Aridis focuses on anti-infective alternatives to conventional antibiotics.


Oct 30th, 2013. Aridis Awarded $17.4M National Institutes of Health (NIH) Contract to Develop Gallium-Based Anti-Infectives. (More)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

May 15th, 2013. Aridis Pharmaceuticals Announces the Acquisition of Monoclonal Antibody Products and Technologies from Kenta Biotech.  (More)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

August 22nd, 2012. Manufacturing agreement with a commercial partner is completed, paving the way for GMP manufacturing of AerucinTM anti-Pseudomonas aeruginosa monoclonal antibody.

News


>> More News


In hospitals, 190 million doses of antibiotics are administered each day.  133 million courses of antibiotics are prescribed by doctors each year”

American College of Physicians

www.acponline.org [02 February 2013]

Our anti-infective drug candidates offer

substantial improvement over conventional antibiotics in: